91 related articles for article (PubMed ID: 23560872)
1. Comparison of injection dose force, accuracy and precision among three growth hormone injection devices.
Kappelgaard AM; Hansen NÅ
Expert Rev Med Devices; 2013 May; 10(3):321-7. PubMed ID: 23560872
[TBL] [Abstract][Full Text] [Related]
2. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens.
Rohrer TR; Winter F; Qvist M; Kappelgaard AM
Expert Opin Drug Deliv; 2013 Dec; 10(12):1603-12. PubMed ID: 24073645
[TBL] [Abstract][Full Text] [Related]
4. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
[TBL] [Abstract][Full Text] [Related]
5. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
Adachi M
J Pediatr Endocrinol Metab; 2013; 26(11-12):1105-10. PubMed ID: 23843576
[TBL] [Abstract][Full Text] [Related]
6. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens.
Ignaut DA; Opincar MR; Clark PE; Palaisa MK; Lenox SM
Curr Med Res Opin; 2009 Dec; 25(12):2829-33. PubMed ID: 19916727
[TBL] [Abstract][Full Text] [Related]
7. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
Pollock RF; Qian Y; Wisniewski T; Seitz L; Kappelgaard AM
Med Devices (Auckl); 2013; 6():107-14. PubMed ID: 23946672
[TBL] [Abstract][Full Text] [Related]
8. Developments in administration of growth hormone treatment: focus on Norditropin® Flexpro®.
Yuen KC; Amin R
Patient Prefer Adherence; 2011 Mar; 5():117-24. PubMed ID: 21448295
[TBL] [Abstract][Full Text] [Related]
9. User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.
Tauber M; Jaquet D; Jesuran-Perelroizen M; Petrus M; Bertrand AM; Coutant R;
Patient Prefer Adherence; 2013; 7():455-62. PubMed ID: 23737664
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone delivery devices: current features and potential for enhanced treatment adherence.
Rohrer TR; Horikawa R; Kappelgaard AM
Expert Opin Drug Deliv; 2017 Nov; 14(11):1253-1264. PubMed ID: 27718757
[TBL] [Abstract][Full Text] [Related]
11. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay.
Meinhardt U; Eiholzer U; Seitz L; Bøgelund M; Kappelgaard AM
Expert Rev Med Devices; 2014 Jan; 11(1):31-8. PubMed ID: 24308742
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
Pawlikowska-Haddal A
Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
[TBL] [Abstract][Full Text] [Related]
13. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen.
Wielandt JO; Niemeyer M; Hansen MR; Bucher D; Thomsen NB
Expert Opin Drug Deliv; 2011 Oct; 8(10):1271-6. PubMed ID: 21883036
[TBL] [Abstract][Full Text] [Related]
14. Liquid growth hormone: preservatives and buffers.
Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
[TBL] [Abstract][Full Text] [Related]
15. Easypod: a new electronic injection device for growth hormone.
Dahlgren J
Expert Rev Med Devices; 2008 May; 5(3):297-304. PubMed ID: 18452378
[TBL] [Abstract][Full Text] [Related]
16. Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.
Hokken-Koelega A; Keller A; Rakov V; Kipper S; Dahlgren J
ISRN Endocrinol; 2011; 2011():803948. PubMed ID: 22363887
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Growth Hormone Devices: Matching Devices with Patients.
Raimer-Hall D; Shea HC
Pediatr Nurs; 2015; 41(2):72-7. PubMed ID: 26292454
[TBL] [Abstract][Full Text] [Related]
18. Cost minimization analysis of different growth hormone pen devices based on time-and-motion simulations.
Nickman NA; Haak SW; Kim J
BMC Nurs; 2010 Apr; 9():6. PubMed ID: 20377905
[TBL] [Abstract][Full Text] [Related]
19. Patient evaluation of a new injection pen for growth hormone treatment in children and adults.
Sjöblom K; Albertsson-Wikland K; Bengtsson BA; Johannsson G; Thorén M; Degerblad M; Savage MO
Acta Paediatr Suppl; 1995 Sep; 411():63-5. PubMed ID: 8563072
[TBL] [Abstract][Full Text] [Related]
20. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
